# A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

> **NCT03315507** · PHASE1 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 3 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** PB1046 Subcutaneous Injection

## Key facts

- **NCT ID:** NCT03315507
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2019-08-08
- **Final completion:** 2019-08-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315507, "A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03315507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*